Hence, cGAS-STING inhibition has the potential to decrease obesity-associated inflammation, type 2 diabetes mellitus (T2DM), NASH/NAFLD, defective wound healing, and angiogenesis. The gene discussed is STING1; the disease is metabolic dysfunction-associated steatohepatitis.